Boston Scientific Acquires Penumbra for $14.5 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy PEN?
Source: NASDAQ.COM
Penumbra Inc. shares surged by 12.25% as the stock reached a 52-week high following the announcement of its acquisition by Boston Scientific for $374 per share in a cash and stock deal valued at approximately $14.5 billion.
The acquisition allows Boston Scientific to expand into the mechanical thrombectomy and neurovascular markets, addressing the growing demand for vascular disease treatments. The deal is expected to be financed through a combination of cash and new debt, with initial earnings per share dilution anticipated, but a neutral to slightly accretive impact expected in the second year. This strategic move highlights Penumbra's strong market position and innovative product offerings in the healthcare sector.
This acquisition not only enhances Boston Scientific's competitive edge but also underscores Penumbra's significant role in the medical technology landscape, potentially leading to increased investor confidence and market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PEN
Wall Street analysts forecast PEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 344.64 USD with a low forecast of 266.00 USD and a high forecast of 388.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 342.010
Low
266.00
Averages
344.64
High
388.00
Current: 342.010
Low
266.00
Averages
344.64
High
388.00
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Q4 Earnings Exceed Expectations but Guidance Falls Short
- Strong Performance: Boston Scientific reported a 16% increase in sales and a 14% rise in adjusted EPS for Q4, exceeding Wall Street expectations and showcasing robust performance in cardiovascular and med-surg technologies.
- Market Reaction: Despite impressive earnings, the company's slightly lower guidance for Q1 and 2026 led to a 16% drop in stock price, reflecting the market's high expectations for future growth.
- Core Business Growth: The cardiovascular segment saw an 18% sales increase, while the med-surg unit grew revenue by 12%, achieving over 12% sales growth in every geography covered, indicating strong performance across markets.
- Future Outlook: Projected sales growth of 11.25% in 2026 and a forecasted $4.2 billion in free cash flow highlight the company's ongoing innovation and investment potential, suggesting that despite short-term stock fluctuations, the long-term growth outlook remains positive.
See More
Boston Scientific Reports Strong Q4 and Full Year 2025 Results
- Significant Sales Growth: Boston Scientific achieved net sales of $5.286 billion in Q4 2025, representing a 15.9% increase, with an organic growth rate of 12.7%, indicating strong market demand and competitiveness in the medical technology sector.
- Improved Profitability: The company reported GAAP net income of $672 million in Q4, translating to an EPS of $0.45, a notable increase from $566 million and $0.38 a year ago, reflecting successful cost control and operational efficiency.
- Strong Annual Performance: For the full year 2025, net sales reached $20.074 billion, up 19.9% with an organic growth rate of 15.8%, demonstrating the company's ongoing expansion and innovation capabilities in the global market.
- Optimistic Future Outlook: The company projects net sales growth of 10.5% to 11.5% for 2026, with adjusted EPS expected to be between $3.43 and $3.49, showcasing management's confidence in future performance and market potential.
See More
Boston Scientific Reports Significant Growth in Q4 2025 Earnings
- Sales Growth: Boston Scientific achieved net sales of $5.286 billion in Q4 2025, representing a 15.9% increase, exceeding the company's guidance of 14.5% to 16.5%, indicating strong market demand and product innovation capabilities.
- Profit Improvement: The company reported GAAP net income of $672 million, or $0.45 per share, compared to $566 million and $0.38 a year ago, reflecting a significant enhancement in profitability that boosts investor confidence.
- Strong Annual Performance: For the full year 2025, net sales reached $20.074 billion, growing 19.9%, with adjusted EPS of $3.06, a 22% increase from the previous year, showcasing the company's sustained leadership in the medical technology sector.
- Optimistic Outlook: The company projects net sales growth of 10.5% to 11.5% for 2026, with adjusted EPS expected between $3.43 and $3.49, indicating management's confidence in future performance and market potential.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Initiated: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) regarding its sale to GSK plc for $58.00 per share, potentially violating fiduciary duties to shareholders and impacting shareholder rights.
- Shareholder Rights Protection: The transaction between Penumbra, Inc. (NYSE: PEN) and Boston Scientific Corporation involves $374.00 in cash or 3.8721 shares of Boston Scientific common stock per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
- Cash and Stock Transaction: Calavo Growers, Inc. (NASDAQ: CVGW) is selling to Mission Produce, Inc. for $14.85 in cash and 0.9790 shares of Mission stock per share, prompting Halper Sadeh LLC to assess the potential impact of this transaction on shareholders.
- Management Transaction Review: FONAR Corporation (NASDAQ: FONR) is involved in a transaction with its CEO and certain executives for $19.00 per share for Class B common stock and $6.34 per share for Class C common stock, with Halper Sadeh LLC possibly advocating for enhanced shareholder rights.
See More
Investigation Alerts for Multiple Company Mergers
- RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, totaling an estimated equity value of $2.2 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- Calavo Merger Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the transaction at approximately $430 million, while investigations examine if the board breached fiduciary duties to shareholders.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valuing the company at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations looking into whether the board ensured a fair process, potentially affecting shareholder interests.
- FONAR Merger Investigation: FONAR Corporation is to be acquired by FONAR, LLC for $19 per share in an all-cash transaction, with investigations questioning whether the board failed to conduct a fair process, which could impact shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Nathan’s Famous, Inc. (NASDAQ: NATH) for potential violations related to its sale to Smithfield Foods, Inc. for $102.00 per share in cash, aiming to protect shareholder rights and seek increased compensation.
- Transaction Details: Penumbra, Inc. (NYSE: PEN) is being sold for $374.00 in cash or 3.8721 shares of Boston Scientific common stock, with Halper Sadeh LLC potentially advocating for more information and compensation to ensure transaction transparency for shareholders.
- Legal Rights: RAPT Therapeutics, Inc. (NASDAQ: RAPT) is selling to GSK plc for $58.00 per share, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and options, ensuring their interests are safeguarded in the transaction.
- Shareholder Support: Lisata Therapeutics, Inc. (NASDAQ: LSTA) is being sold for $4.00 per share in cash plus two non-tradeable rights, with Halper Sadeh LLC offering contingent fee legal services to help shareholders secure their rightful interests in the potential transaction.
See More
Boston Scientific Q4 Earnings Exceed Expectations but Guidance Falls Short
- Strong Performance: Boston Scientific reported a 16% increase in sales and a 14% rise in adjusted EPS for Q4, exceeding Wall Street expectations and showcasing robust performance in cardiovascular and med-surg technologies.
- Market Reaction: Despite impressive earnings, the company's slightly lower guidance for Q1 and 2026 led to a 16% drop in stock price, reflecting the market's high expectations for future growth.
- Core Business Growth: The cardiovascular segment saw an 18% sales increase, while the med-surg unit grew revenue by 12%, achieving over 12% sales growth in every geography covered, indicating strong performance across markets.
- Future Outlook: Projected sales growth of 11.25% in 2026 and a forecasted $4.2 billion in free cash flow highlight the company's ongoing innovation and investment potential, suggesting that despite short-term stock fluctuations, the long-term growth outlook remains positive.
See More
Boston Scientific Reports Strong Q4 and Full Year 2025 Results
- Significant Sales Growth: Boston Scientific achieved net sales of $5.286 billion in Q4 2025, representing a 15.9% increase, with an organic growth rate of 12.7%, indicating strong market demand and competitiveness in the medical technology sector.
- Improved Profitability: The company reported GAAP net income of $672 million in Q4, translating to an EPS of $0.45, a notable increase from $566 million and $0.38 a year ago, reflecting successful cost control and operational efficiency.
- Strong Annual Performance: For the full year 2025, net sales reached $20.074 billion, up 19.9% with an organic growth rate of 15.8%, demonstrating the company's ongoing expansion and innovation capabilities in the global market.
- Optimistic Future Outlook: The company projects net sales growth of 10.5% to 11.5% for 2026, with adjusted EPS expected to be between $3.43 and $3.49, showcasing management's confidence in future performance and market potential.
See More
Boston Scientific Reports Significant Growth in Q4 2025 Earnings
- Sales Growth: Boston Scientific achieved net sales of $5.286 billion in Q4 2025, representing a 15.9% increase, exceeding the company's guidance of 14.5% to 16.5%, indicating strong market demand and product innovation capabilities.
- Profit Improvement: The company reported GAAP net income of $672 million, or $0.45 per share, compared to $566 million and $0.38 a year ago, reflecting a significant enhancement in profitability that boosts investor confidence.
- Strong Annual Performance: For the full year 2025, net sales reached $20.074 billion, growing 19.9%, with adjusted EPS of $3.06, a 22% increase from the previous year, showcasing the company's sustained leadership in the medical technology sector.
- Optimistic Outlook: The company projects net sales growth of 10.5% to 11.5% for 2026, with adjusted EPS expected between $3.43 and $3.49, indicating management's confidence in future performance and market potential.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Initiated: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) regarding its sale to GSK plc for $58.00 per share, potentially violating fiduciary duties to shareholders and impacting shareholder rights.
- Shareholder Rights Protection: The transaction between Penumbra, Inc. (NYSE: PEN) and Boston Scientific Corporation involves $374.00 in cash or 3.8721 shares of Boston Scientific common stock per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
- Cash and Stock Transaction: Calavo Growers, Inc. (NASDAQ: CVGW) is selling to Mission Produce, Inc. for $14.85 in cash and 0.9790 shares of Mission stock per share, prompting Halper Sadeh LLC to assess the potential impact of this transaction on shareholders.
- Management Transaction Review: FONAR Corporation (NASDAQ: FONR) is involved in a transaction with its CEO and certain executives for $19.00 per share for Class B common stock and $6.34 per share for Class C common stock, with Halper Sadeh LLC possibly advocating for enhanced shareholder rights.
See More
Investigation Alerts for Multiple Company Mergers
- RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, totaling an estimated equity value of $2.2 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- Calavo Merger Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the transaction at approximately $430 million, while investigations examine if the board breached fiduciary duties to shareholders.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valuing the company at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations looking into whether the board ensured a fair process, potentially affecting shareholder interests.
- FONAR Merger Investigation: FONAR Corporation is to be acquired by FONAR, LLC for $19 per share in an all-cash transaction, with investigations questioning whether the board failed to conduct a fair process, which could impact shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Nathan’s Famous, Inc. (NASDAQ: NATH) for potential violations related to its sale to Smithfield Foods, Inc. for $102.00 per share in cash, aiming to protect shareholder rights and seek increased compensation.
- Transaction Details: Penumbra, Inc. (NYSE: PEN) is being sold for $374.00 in cash or 3.8721 shares of Boston Scientific common stock, with Halper Sadeh LLC potentially advocating for more information and compensation to ensure transaction transparency for shareholders.
- Legal Rights: RAPT Therapeutics, Inc. (NASDAQ: RAPT) is selling to GSK plc for $58.00 per share, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and options, ensuring their interests are safeguarded in the transaction.
- Shareholder Support: Lisata Therapeutics, Inc. (NASDAQ: LSTA) is being sold for $4.00 per share in cash plus two non-tradeable rights, with Halper Sadeh LLC offering contingent fee legal services to help shareholders secure their rightful interests in the potential transaction.
See More
